Month: May 2025

LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) — Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resignation of its Chair. Mr. Ross Haghighat tendered his resignation on May 24th and it was accepted by the Sernova Board. The Board of Directors of Sernova thanks Ross for his service as a trusted leader and sincerely wishes him luck in the future. ABOUT SERNOVA BIOTHERAPEUTICS Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create Bio-hybrid Organs to treat T1D. A Bio-hybrid...

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, May 26, 2025 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) (TSX,OSE:QEC) reported on the recent ruling by the Court of Appeal of Quebec related to Bill 21, An Act ending exploration for petroleum and underground reservoirs and production of petroleum and brine (“Bill 21”). A copy of the ruling in French is available online: https://courdappelduquebec.ca/fileadmin/jugements/200-09-010731-245_Arret_2025-05-22.pdf. Michael Binnion, President and Chief Executive Officer of Questerre, commented, “In its ruling, the Court of Appeal recognized the existence of a serious issue with respect to the constitutionality of Bill 21 and reinstated...

Project Credit Facility through AFG Bank Cameroon, along with Option Exercise by Eagle Eye Asset Holdings to Fund Stage One Operations PERTH, Australia, May 25, 2025 (GLOBE NEWSWIRE) — Canyon Resources Limited (ASX: CAY) (‘Canyon’ or the ‘Company’) is pleased to announce that its wholly owned in-country subsidiary, Camalco Cameroon SA (‘Camalco’) has signed a binding agreement with AFG Bank Cameroon (‘AFG Bank CM’) for a medium-term syndicated credit facility of XAF 82,000,000,000 (~US$140M) (‘Credit Facility’). Canyon will use the credit facility for the acquisition of locomotives, wagons, the development of rail, ore transport infrastructure and the port facility for the flagship Minim Martap Bauxite Project (‘Minim Martap’ or ‘the Project’), located in Cameroon. Importantly, the ~US$140 million Credit Facility, along with the...

TEL AVIV, Israel, May 25, 2025 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today announced that Glass Lewis, a leading independent proxy advisory firm, has recommended that stockholders vote “FOR” the compensation proposal for Radware’s president and chief executive officer at the Company’s upcoming Extraordinary General Meeting of Shareholders (the ”Extraordinary General Meeting” or the “Meeting”). In its report, Glass Lewis found that the annual bonus and long-term equity incentives are appropriately aligned with both performance and prevailing market practices. “We are pleased that Glass Lewis supports our proposal for the modification of the compensation structure for Radware’s president and chief executive officer,” said Meir Moshe,...

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a favorable safety and tolerability profile – RADNOR, Pa., May 24, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone,...

Oslo, 24 May 2025: Zelluna ASA (the “Company”) refers to the resolution by the Company’s Annual General Meeting held on 29 April 2025 to grant the Company’s Board of Directors an authorisation to issue new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The Company’s Board of Directors has today resolved to issue 227,096 new shares in the Company to Inven2 against set-off of such amount of EUR 500,000. After the share capital increase related to the issuance of the new shares has been registered with the Norwegian Register of Business Enterprises, the Company will have a share capital of NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. For further information, please contact: Hans...

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States Fredericton, New Brunswick, May 23, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) announces, further to its news releases of April 1, 2025, April 29, 2025, May 8, 2025, and May 16, 2025 that the Company has completed the third and final tranche (the “Third Tranche”) of its previously announced non-brokered private placement (the “Offering”). Pursuant to the Third Tranche, the Company issued 2,468,032 special warrants (the “Special Warrants”) at the price of $0.30 per Special Warrant for gross proceeds of $740,409.74.In connection with the Third Tranche, the Company paid...